Cardiac Diagnostics and the Challenge of ER Testing
More than 10 years after it was introduced on a broad scale in non-glucose applications, point-of-care testing (POCT) has found a place in carefully selected niches in hospitals. It's still not part of mainstream care, however. Data indicating the importance of getting rapid test results on cardiac markers, notably troponins and BNP, is tempting POCT in vitro diagnostics manufacturers to forge closer relationships with non-lab clinicians, even as they cater to their core, but resistant, laboratory customer base. Manufacturers are going to have to make their devices smaller, easier to use, cheaper, and better connected to data management systems if they want to lower the central labs' resistance to POCT.
by Wendy Diller
The year 2002 would seem to have been good for manufacturers of point-of-care cardiac diagnostic markers. Significant research papers and updates to professional guidelines linked several biochemical cardiac markers ever...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
